Start New EnglishEspañol中文РусскийالعربيةTiếng ViệtFrançaisDeutsch한국어Tagalog Library Performance
BETA v.3.0

2025 ICD-10-CM code C80.0

Disseminated malignant neoplasm, unspecified. Cancerous growth affecting multiple body areas, often spreading through the bloodstream, primarily seen in immunocompromised individuals. The specific site(s) affected are unspecified.

Use this code only when the primary site of the malignancy cannot be determined despite thorough investigation. Do not use this code if a primary site can be identified, even if the cancer has metastasized widely.

Medical necessity for treatment is based on the confirmed diagnosis of disseminated malignancy, the patient's overall health condition, and the potential benefits and risks of the chosen treatment approach.

Diagnosis involves patient history, symptoms, physical examination, and diagnostic procedures (tumor marker tests, biopsy, CT, MRI, PET scans) depending on the site(s) affected. Treatment, including surgery, chemotherapy, and/or radiotherapy, depends on the cancer's stage, location, and resectability.

In simple words: Cancer that has spread to many parts of the body. The original location of the cancer is unknown.

Disseminated malignant neoplasm refers to a cancerous growth of cells that has spread to multiple areas of the body.This spread, often occurring via the bloodstream, typically affects individuals with compromised immune systems.The primary site of the neoplasm is unknown.

Example 1: A patient presents with widespread tumors and symptoms in multiple organs, but the origin of the cancer cannot be determined after extensive testing. The diagnosis of disseminated malignant neoplasm, unspecified (C80.0) is given., An immunocompromised patient develops multiple tumors throughout the body. Biopsies and imaging studies confirm malignancy, but a primary site cannot be identified. C80.0 is used., A patient with a history of cancer of unknown origin presents with new tumors in several locations.The new tumors are consistent with metastatic disease. C80.0 is applied.

Documentation should include evidence of widespread malignancy, details of diagnostic tests performed (e.g., biopsy results, imaging reports), and efforts made to identify a primary site, along with the clinical rationale for concluding that the primary site is unknown.

** Only Enterprise users with EHR integration can access case-specific answers. Click here to request access.

Discover what matters.

iFrame™ AI's knowledge is aligned with and limited to the materials uploaded by users and should not be interpreted as medical, legal, or any other form of advice by iFrame™.